0001213900-26-057695
SEC filingRevenue surged 90% to $1.4M from higher surgical procedures and SImmetry+ System adoption, expanding gross margins to 68.5% via production leverage, though operating losses narrowed modestly amid investment pressures and liquidity concerns.
Revenue increased 89.9% to $1.4 million for Q1 FY2026 from $726 thousand in the prior year, primarily due to higher surgical procedure volumes and the addition of revenue from The SImmetry+ System. This reflects growing adoption of the company's dual-system portfolio—The Catamaran System and The SImmetry+ System—which targets sacro-pelvic fixation through minimally invasive techniques. Management highlights that expanded case volumes and new product contributions drove this acceleration, signaling commercial progress in the SI joint fusion market despite quarterly variability from clinician and sales rep activities.
Gross profit rose 192.6% to $945 thousand, achieving a 68.5% gross margin, up significantly from the prior period. This improvement stemmed from absorption of production overhead into standard costs and operating leverage from lower relative fixed costs against increased revenue volume. The company utilizes contract manufacturers for implants and tray sets of both The Catamaran and SImmetry+ Systems, enabling scalable production that benefits from volume gains without proportional cost increases. Investors should note this margin trajectory as evidence of manufacturing efficiency gains supporting scalability.
Operating loss improved 10.8% to -$3.3 million from -$3.7 million prior year, with operating margin at -237.9%. Revenue growth offset rising general and administrative expenses tied to business expansion, including payroll, professional services, and insurance, partially mitigated by lower stock-based compensation. Management expects operating expenses to rise in absolute dollars to fuel growth, though G&A as a percentage of revenue should decline over time with scale.
Net loss narrowed 3.9% to -$3.5 million, with diluted EPS at $0.31 versus -$1.01 last year. Net cash used in operating activities was -$2.96 million, plus $56 thousand in capital expenditures, yielding -$3.0 million free cash flow—worse than prior year on working capital timing.